NCT05832892 2024-06-14
Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer
Shanghai Zhongshan Hospital
Phase 1/2 Unknown
Clinical Trials
20 trialsNCT02037048 2024-01-08
FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma
Case Comprehensive Cancer Center
Phase 2 Unknown
NCT04902261 2023-09-01
Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer
Changhai Hospital
Phase 2 Unknown
NCT04267549 2023-07-06
Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT02560298 2023-06-22
InterAACT
Eastern Cooperative Oncology Group
Phase 2 Unknown
NCT05634564 2022-12-05
Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT05327582 2022-04-14
An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT05298020 2022-03-28
Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer
The Affiliated Hospital of Xuzhou Medical University
Phase 2 Unknown
NCT04617821 2022-01-28
AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer
Fudan University
Phase 3 Unknown
NCT05047991 2021-09-17
Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 2 Unknown
NCT04835064 2021-04-08
Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.
Fudan University
Phase 3 Unknown
NCT04808687 2021-03-22
Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT03703063 2021-01-27
Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer
Benaroya Research Institute
Phase 1 Unknown
NCT04498689 2020-08-04
Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer
Fudan University
Phase 2 Unknown
NCT04443036 2020-06-23
Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma
China Medical University, China
Phase NA Unknown
NCT04135781 2020-03-23
Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage â…¢ Gastric Cancer
Zhejiang Cancer Hospital
Phase 3 Unknown
NCT03668418 2018-09-12
xenoZ
University of Pisa
Unknown
NCT03636308 2018-08-17
ASAGPAC
Peking University
Phase 2 Unknown
NCT02124317 2016-12-22
NAPSPAC
Chinese PLA General Hospital
Phase 2 Unknown
NCT02135822 2014-05-16
NAPGAP
Chinese PLA General Hospital
Phase 2 Unknown